{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-031133","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.351759+00:00","generated_at":"2026-05-30T15:29:55.231569+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NRx CEO resigns; Chairman Javitt takes interim CEO; shareholders approve reverse split","bullets":["CEO Stephen Willard resigns effective Oct 7, 2024; Chairman Jonathan Javitt appointed interim CEO.","Stockholders approved reverse stock split authorization (1:2 to 1:5) at board's discretion within one year.","Stockholders approved issuance of shares upon redemption of convertible note and warrants to institutional investors.","Company signed LOI to acquire an interventional psychiatry clinic; targeting $25M+ initial HOPE Therapeutics business and $100M+ revenue by next year."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-031133","json":"https://secwatch.observer/filing/0001437749-24-031133.json","markdown":"https://secwatch.observer/filing/0001437749-24-031133.md","text":"https://secwatch.observer/filing/0001437749-24-031133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/0001437749-24-031133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/nrxp20241011_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:29:55.231569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07c960c804","claim":"Jonathan Javitt was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/0001437749-24-031133-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cd328e024d","claim":"Stephen Willard resigned as Chief Executive Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/0001437749-24-031133-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}